Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Giessen – page 2

248 clinical trials in Giessen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Giessen at a glance
248
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

248 trials in Giessen

Open in trial search

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Factor VIII deficiency+1

Recruiting

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Non-Hodgkin's lymphoma

Recruiting

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Merck Sharp & Dohme LLC

Pulmonary arterial hypertension

Recruiting

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Rinatabart Sesutecan with Pegfilgrastim in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Post-acute COVID-19 syndrome

Recruiting

Randomized trial of bupropion hydrochloride for fatigue in patients with long COVID (post‑COVID syndrome)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bupropion Hydrochloride
  • Sponsor:Goethe University Frankfurt

Idiopathic pulmonary fibrosis

Recruiting

Study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nintedanib
  • Sponsor:Avalyn Pharma Inc.

Neurodevelopmental disorder

Recruiting

A study to evaluate the effects of N-Acetyl-L-Leucine in patients with CACNA1A disorders

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:L-Acetylleucine
  • Sponsor:IntraBio Inc

Small cell lung cancer

Recruiting

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary arterial hypertension

Recruiting

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
  • Sponsor:Regeneron Pharmaceuticals Inc.

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Giessen

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on pulmonary hypertension and lung cancer treatments, including evaluation of novel therapies for various stages of NSCLC and rare pulmonary conditions.

  • Pulmonary Arterial Hypertension
  • Non-Small Cell Lung Cancer
  • Idiopathic Pulmonary Fibrosis

Multiple studies are investigating targeted therapies and combination treatments for advanced lung diseases.

02 Rare Disease Studies

Comprehensive research into rare genetic conditions, including Leber congenital amaurosis and Niemann-Pick disease, with trials testing innovative therapeutic approaches.

  • Ataxia Telangiectasia
  • Spinal Muscular Atrophy
  • Hunter Syndrome

These studies aim to improve treatment options for patients with rare genetic disorders.

03 Oncology Research

Advanced clinical trials examining new treatments for various cancers, particularly focusing on head and neck cancer and innovative immunotherapy combinations.

  • Metastatic Lung Cancer
  • Ovarian Cancer
  • Squamous Cell Carcinoma

Studies are evaluating novel drug combinations and targeted therapies for better treatment outcomes.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.